Oncolytics Biotech Inc ONCY

Buyout numbers

[CaseyL]

Could we fetch 7 billion in a buyout? I would really like to hear Notables take an it.

[Noteable]

I've already provided my take, particularly since ONCY has targeted the metastatic pancreatic, breast,  and colorectal cancer markets with a biomarker driven biological in the form of  pelareorep, which is eligible for 13 years of FDA market exclusivity on each indication approved. And the markets for these cancers are significant as already stated.

[canadafan]

A buy out number? Depens on when. The closer we get to approval the higher the price goes. Once phase 3 start is announced. Regardless of how the busness model is structured.  THAT wlll be a HUGE validation of the machine moving forward. Predictions of mine? Based on analysts assesments etc  Assuimimg a quick buy-out, being next few months, pre-partnership. That would be $1.5 billion

[fox7mf]

Hey Lee, welcome. Don't mind Canadafan, he's like ALWAYS wrong:) As for cranky Noteable, he's on record predicting a number between $10b- $15b...fingers crossed;)

[Azzak34]

Don't worry about Fox's passive aggressive tone, he's "like" always a complete tool. 

[canadafan]

Hey if it comes in at $10-$15 billion, Id be quite happy to be wrong. I gave my justifications for the numbers. I well apreciate there are those who think that my $1.5 - $5 billion is silly low. others think  Silly  high. Regardless, we will only know , when it happens, not before. I have been a shareholder of 6-7 companies that were bought out. Trust me: They were all a surprise

[Buckhenry]

I have blocked most of the forever pumpers but I can just hear them now. They went ape sh!t on stocktwits so I would figure the same on this site. I will wait for NR before I go buy that yacht. 

[Azzak34]

You don't have shares here or you wouldn't constantly FUD against it.  What's your name on Stocktwits? You FUDDING over there too? 

[fox7mf]

In any event, let's make up the 40 plus cents lost last week before we talk about buyouts. Good day, but we are still 50% down from the 52 week high.

[Noteable]

With Roche's US$ 7.1 Billion acquisition price for an experimental drug in ulcerative colitis,  ONCY's buy out potential is certainly north of there, for reasons already provided including Big Pharma's looming patent cliff and Roche's strategy around Tecentriq.

[venture009]

https://www.ft.com/content/99d8bdb4-b854-411f-b3b4-fcb6f94f8292 This article is interesting from the perspective that Roche has not had much success when it comes to aquisitions and PIII, and the market has punished them. They will be very cautious. Should we expect an imminent offer. The $billion question. Let's hope they have had enough experience with pela to make an offer. 

[Noteable]

The global ulcerative colitis market was valued at USD $7.1 billion in 2020, and is projected to reach USD$10.8 billion by 2030. - so growth in this market segment appears to have matured, yet Roche decided to acquire Telavant for USD $7.1billion, presumably in part, on the strength of biomarker data in Riovants Phase2b study.   Conversely, the global pancreatic cancer market was valued

[Noteable]

With Roche's US$ 7.1 Billion acquisition price for an experimental drug in ulcerative colitis,  ONCY's buy out potential is certainly north of there, for te following reasons including Big Pharma's looming patent cliff and Roche's strategy around Tecentriq. The global ulcerative colitis market was valued at USD $7.1 billion in 2020, and is projected to reach USD$10.8

[CaseyL]

Thank you for your input Noteable. Happy Thanksgiving, American time. if you're not Canadian.